Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BOIRON Interim / Quarterly Report 2015

Jul 17, 2015

1161_iss_2015-07-17_2e47285e-7fef-4b90-a105-fffb25718c45.pdf

Interim / Quarterly Report

Open in viewer

Opens in your device viewer

2015 HALF-YEAR ACTIVITY

(Unaudited data)

CUMULATIVE ACTIVITY AS OF THE END OF JUNE 2015

2014 2015 Variation at Variation at
thousands of euros current constant
exchange rates exchange rates
France 157,018 166,448 + 6.0% + 6.0%
Europe (excluding France) 73,537 70,600 - 4.0% - 2.6%
North America 23,287 30,087 + 29.2% + 7.7%
Other countries 7,774 8,438 + 8.5% + 9.7%
Group total 261,616 275,573 + 5.3% + 3.9%
2014 2015 Variation at Variation at
thousands of euros current constant
exchange rates exchange rates
Non-proprietary Homeopathic Medicines 150,991 153,545 + 1.7% + 0.7%
OTC Specialties 110,254 121,910 + 10.6% + 8.4%
Other 371 118 - 68.2% - 43.9%
Group total 261,616 275,573 + 5.3% + 3.9%

ACTIVITY IN THE QUARTER (variation at current rate)

1st Quarter 2nd Quarter
thousands of euros 2014 2015 Var.
15/14
2014 2015 Var.
15/14
France 82,749 89,584 +8.3% 74,269 76,864 +3.5%
Europe (excluding France) 39,967 40,657 +1.7% 33,570 29,943 -10.8%
North America 12,662 17,193 +35.8% 10,625 12,894 +21.4%
Other countries 4,831 4,622 -4.3% 2,943 3,816 +29.7%
Group total 140,209 152,056 +8.4% 121,407 123,517 +1.7%
1st Quarter 2nd Quarter
thousands of euros 2014 2015 Var. 2014 2015 Var.
15/14 15/14
Non-proprietary Homeopathic Medicines 77,919 79,191 +1.6% 73,072 74,354 +1.8%
OTC Specialties 62,196 72,880 +17.2% 48,058 49,030 +2.0%
Other 94 -15 - 277 133 -52.0%
Group total 140,209 152,056 +8.4% 121,407 123,517 +1.7%

HIGHLIGHTS OF THE SECOND QUARTER 2015

Sales in the second quarter of 2015 rose by 1.7% compared to the second quarter of 2014: business activity increased in France and the US and decreased, especially, in Russia, Spain and Poland.

Profitability in the first half of 2015 should rise compared to 2014.

BOIRON will continue its involvement in the development of homeopathy with confidence and ambition. Taking into account the geopolitical risks, especially in Russia, the BOIRON group remains cautious in its outlook for 2015.

Our next update:

Person responsible for financial information: Christian Boiron

Contact for financial information: Véronique Bouscayrol

Investor relations: +33 (0) 4.78.45.63.43 - e-mail : [email protected]

ISIN Code: FR0000061129 (BOI) - Bloomberg : BOI FP - Reuters : BOIR.PA

The group's financial information is online at: www.boironfinance.com

September 3, 2015: at market close, publication of 2015 half-year results.